Normal

February 6th -7th, 2020

5th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference

Sheraton San Diego Hotel & Marina, 1380 Harbor Island Dr, CA 92101, United States

30+

Speaker

10+

Networking Hours

4

Sessions

200+

Attendees

The 5th Annual Biomarker and Companion Diagnostics Conference scheduled to be held on 6th - 7th February 2020 in San Diego, CA would address the gaps between early-stage biomarker development and the commercialization stage of biomarkers. This conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers, Precision Medicine and Big Data. Regarding the commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in the companion diagnostics areas. The keynote presentations would also help the attendees understand the issues related to clinical translation of biomarkers.

30+ experts from academia and industry will be presenting their current work in Biomarkers, Latest updates on regulatory guidelines and approvals, Cancer biomarker validation for clinical application, Biomarkers and Personalized Medicine, Impact of Big data in translational biomarker research and Future of Companion Diagnostics

Opportunity to develop long-lasting business relationships and networking opportunities with researchers, scientists, clinicians, academicians and professionals from Pharmaceutical companies, Bio-pharma companies, Universities, and Research institutes.

Over 20 presentations, round-tables, and panel discussions focused on the key opportunities and challenges in biomarker research, from precision medicine and companion diagnostics through to digital biomarkers and clinical trials.

This two-day event will invite 200+ biomarker discovery professionals, 30+ expert speakers and 15+ solution/technology providers to a unique platform to deliver niche buyer-seller ecosystem in the biomarker Industry.

WHAT TO EXPECT

Who Should Attend

Researchers, Scientists & Clinicians who are active in:

Biomarker discovery/development
Translational research
Clinical Biomarker
Biomarkers in IO and Neurological disorders
Imaging Biomarkers
Companion Diagnostics
Biomarker Imaging
Proteomics Biomarkers
Experimental Medicine
Data Science
Biomarkers in Clinical Discovery
Immuno-oncology/Neuroscience Drug Discovery
Diagnostic Biomarkers development

Key Highlights

Biomarker Drug Discovery and Assay Development
Proteomics and Genomics based Biomarkers
Digital Biomarkers, Precision Medicine and Big Data
Predictive Biomarkers in targeted Cancer Therapy
CDx development and Commercialization
Clinical Applications of Biomarkers in Immuno-Oncology
Neurology and Inflammatory Diseases

Sessions

Biomarkers In Clinical & Translational Development: Drug Discovery And Assay Development
Innovations In Biomarker Research: Digital Biomarkers, Precision Medicine And Big Data
From Biomarkers To Cdx: Strategies To Accelerate Cdx Development And Commercialization
Clinical Applications Of Biomarkers In Immuno-oncology, Neurology And Inflammatory Diseases

CONFERENCE AGENDA

Day 1 Thu, 06-Feb-2020
Day 2 Fri, 07-Feb-2020

Registration

Welcome note from MarketsandMarkets

08:45 - 09:05 Shekhar Gupta , Geography Head-US, MarketsandMarkets

Opening Remarks from the Chairman

09:05 - 09:10 Naveen Babbar , Executive Director, Precision Medicine Leader, Novartis

Keynote Presentation

09:10 - 09:40 Lokesh Agrawal , Program Director, Biorepositories and Biospecimen Research Branch (BBRB), , NIH

BIOMARKERS IN CLINICAL & TRANSLATIONAL DEVELOPMENT: DRUG DISCOVERY AND ASSAY DEVELOPMENT

New Directions in Biomarkers for CAR-T Therapies in Multiple Myeloma

09:40 - 10:10 Majid Ghoddusi , Senior Director, Clinical Biomarkers, Poseida Therapeutics

Non-invasive Precision Genomics in Dermatology

10:10 - 10:25 Burkhard Jansen , Chief Medical Officer , Dermtech

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

Enhanced Biomarker Discovery and Validation Using TMT® Proteomics

11:10 - 11:40 Jessica McDonough, Co-Founder, Attivare Therapeutics

Interpreting the complexity of cancer with blood-based biomarkers for both tumor and immune profiling

11:40 - 12:10 Linda Traylor , Vice President, Clinical Development & Medical Affairs, Biodesix

Blood-based Traumatic Brain Injury Biomarkers: past, present and future

12:10 - 12:40 Kevin Wang, Director, Program for Neuroproteomics and Biomarkers Research, University of Florida

Streamlined CDx® Program - Accelerating Drug Approvals Worldwide

12:40 - 13:10 Jeffrey Miller, CSO & CEO, Invivoscribe

Lunch and Poster Presentation | One-to-One Networking Meetings

INNOVATIONS IN BIOMARKER RESEARCH: DIGITAL BIOMARKERS, PRECISION MEDICINE AND BIG DATA

Precision Medicine and Immuno-Oncology Drug Development

14:10 - 14:40 Roy Baynes , Senior Vice President and Head Global Clinical Development, Chief Medical Officer, Merck Research Laboratories

AI For Digital Biomarker Discovery

14:40 - 14:55 Christelle Fasano, Senior Director, Business Development, Pharma & Biotech, Imagia

Business of Fit-for-Purpose: From Sample Management to Validation to Final Sample Analysis Data

14:55 - 15:25 Amber Donahue, Biomarker Clinical Assay Lead, Pfizer

Empowering Patients & Physicians: A Novel Clinical Trial for Molecular Disease Characterization

15:25 - 15:55 Kristin Blouch, Director, Head of RWE & Molecular Disease Characterization, Experimental Medicine Unit, GSK

Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings

Using complex genetic/biomarker information to optimize trial design and developing efficient statistical algorithms to identify patient subgroups with better/worse responses/survival profile to a particular treatment

16:40 - 17:10 Vicky Wu, Co-Investigator, Fred Hutch

Developing global and gene specific methylation tools for drug development

17:10 - 17:25 Liying Yan, President, EpigenDx

Panel Discussion: Biomarker strategies and partnering with medical device companies

17:25 - 17:55 Karina Besprosvan , Datastoryteller Insight & Innovation Exponential C, Sony Pictures Entertainment

Closing Remarks from the Chairman

Drinks Reception & Networking

Registration

Welcome note from MarketsandMarkets

Opening Remarks from the Chairman

09:05 - 09:10 Majid Ghoddusi , Senior Director, Clinical Biomarkers, Poseida Therapeutics

Keynote Presentation: Mechanisms of Toxicity, Resistance and Response to anti-CD19 CAR T cell Therapy in LCL

09:10 - 09:40 John Rossi,, Vice President, Head, Translational Medicine, , Syncopation Lifesciences

FROM BIOMARKERS TO CDX: STRATEGIES TO ACCELERATE CDX DEVELOPMENT AND COMMERCIALIZATION

An Integrated Oncology Platform for Biomarker Discovery and Companion Diagnostics Development

09:40 - 10:10 Nicole Niu , Executive Director , Crown Bioscience

Tempus | Making the Promise of Precision Medicine a Reality

10:10 - 10:25 Michael Yasiejko , Chief Commercial Officer, Tempus

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

Integration of biomarker validation in clinical development: a statistical perspective

11:10 - 11:40 Elisabeth Coart, Director, Consulting Services, IDDI

Eutropics’ Praedicare DxTM platform providing predictive functional biomarkers for AML

11:40 - 11:55 Michael Cardone, CEO , Eutropics Pharmaceuticals Inc.

Accurate Plasma Biomarker Detection for Clinical Trials & Clinical Practice: Why Sensitivity Matters

11:55 - 12:10 Dan Edelstein , Vice President, Commercial Operations, Sysmex Inostics

Companion Diagnostic Development in Gene Expression for Challenging Sample Types

12:10 - 12:40 BJ Kerns, Vice President, Scientific Collaborations , HTG Molecular Diagnostics

Companion Diagnostic Development: How to Ensure Program Success

12:40 - 13:10 Kristina McGuire, Senior Director, Regeneron Pharmaceuticals

Lunch and Poster Presentation | One-to-One Networking Meetings

CLINICAL APPLICATIONS OF BIOMARKERS IN IMMUNO-ONCOLOGY, NEUROLOGY AND INFLAMMATORY DISEASES

Increasing Complexity in Tissue Based Diagnostics

14:10 - 14:25 Scott Boyer, Business Development Manager, Leica Biosystems

A universal early cancer screen using a blood-based 400K frameshift peptide array

14:25 - 14:55 Yisrael Katz, Senior Medical Director , Viracta Therapeutics, Inc.

Immuno-Oncology Biomarkers Identified by Novel Digital Pathology Approaches

14:55 - 15:25 Jennifer Bordeaux , Principal Investigator, Navigate BioPharma

Targeting extrachromosomal DNA (ecDNA), a new approach to treating cancers with high copy number gene amplification

15:25 - 15:55 Jason Christiansen, Chief Technology Officer, Boundless Bio

CONFERENCE SPEAKERS

Advisors

Steven Richards

Steven Richards
Investigator, Biomarker Expert, Novartis

Pallavi Sachdev

Pallavi Sachdev
Senior Director, Clinical Pharmacology and Translational Medicine, Eisai

Howard Federoff

Howard Federoff
Professor of Neurology, University of California

Speakers

Shekhar Gupta

Shekhar Gupta
Geography Head-US, MarketsandMarkets

Roy Baynes

Roy Baynes
Senior Vice President and Head Global Clinical Development, Chief Medical Officer, Merck Research Laboratories

John Rossi,

John Rossi,
Vice President, Head, Translational Medicine, , Syncopation Lifesciences

Amber Donahue

Amber Donahue
Biomarker Clinical Assay Lead, Pfizer

Yisrael Katz

Yisrael Katz
Senior Medical Director , Viracta Therapeutics, Inc.

Naveen Babbar

Naveen Babbar
Executive Director, Precision Medicine Leader, Novartis

Vicky Wu

Vicky Wu
Co-Investigator, Fred Hutch

Elisabeth Coart

Elisabeth Coart
Director, Consulting Services, IDDI

SPONSORS

Gold

example-image — International Drug Development Institute

example-image — Proteome Sciences

example-image — Navigate BioPharma Services

example-image — Biodesix

Silver

example-image — Invivoscribe

Sponsors & Exhibitors

example-image — Myriad RBM

example-image — Imagia

example-image — Paragon Genomics

example-image — DermTech

example-image — Flagship Biosciences

example-image — Eutropics

example-image — HTG Molecular Diagnostics, Inc.

example-image — Roche

example-image — Crown Bioscience

example-image — Kypha

example-image — Tempus

example-image — Agilent

example-image — Champions Oncology

example-image — Ordinatrix

example-image — BioIVT

example-image — Avacta Life Sciences

example-image — Leica Biosystems

example-image — PointCross Life Sciences

example-image — Randox

example-image — Sysmex Inostics

example-image — EpigenDx

example-image — QIAGEN

PARTNERS

Supporting Association

California Life Sciences Association (CLSA)

Iowa Biotech Association

Media Partners

example-image — Technology Networks

example-image — PharmaTutor

example-image — Pharma Journalist

example-image — PharmaVOICE

example-image — GEN

LOCATION

Sheraton San Diego Hotel & Marina, 1380 Harbor Island Dr, CA 92101, United States

About the Hotel

Sheraton San Diego Hotel & Marina dazzles guests with waterfront views, sophisticated accommodations and four-star amenities. Benefiting from an excellent location on Harbor Island, our resort places the best of San Diego nearby; enjoy proximity to downtown, Gaslamp Quarter, San Diego Zoo and Petco Park.

Arrive via a complimentary shuttle from San Diego International Airport and refresh in our light-filled accommodations, each featuring its own private balcony or patio, plus signature Sheraton amenities. Waterfront views and finely crafted American cuisine are on display at Harbor's Edge, or stop by Quinn's Ale House for a refreshing microbrew.

Hotel Booking Link

For any queries regarding the hotel booking please write to us at [email protected]

You will receive a link to book your accommodation via email once you are fully registered. (Please note that we do not authorize any 3rd party agencies (e.g. Exhibitors Housing Management) to book on our behalf and, occasionally, companies fraudulently try to represent us. If you are contacted by anyone other than us regarding your accommodation requirements for this event, please let us know immediately on [email protected]

PAST EVENT GALLERY